OPL Cares about Human Health

The World Benefits from OPL’s Technology

About Us

Specializing in oral solid sustained-release technology, sustained-release new drugs, and related fields.
A leading Controlled Release DDS company with a focus to enhance the value of your existing assets (LCM) by offering superior efficacy and safety profiles, convenient to use, extended IP protection, and combination products.
12 years product development effort resulted in rich post-POC pipelines for your fast commercialization.
About 200 Subject-Matter-Experts and Scientists globally to help fulfill your unmet needs.

Core Team Members

Dr.Gilbert

Dr.Gilbert

Wen-Founder and Chairman

Dr.Gilbert Wen-Founder and Chairman

Dr.David Zhao

Dr.David Zhao

Chief Scientific Officer

Dr.David Zhao-Chief Scientific Officer

Dr.John Fan

Dr.John Fan

Chief Technical Officer

Dr.John Fan-Chief Technical Officer

Dr.Huaihan Cai

Dr.Huaihan Cai

Director,Medical Affairs

Dr.Huaihan Cai-Director,Medical Affairs

Dr.Shuo Zhang

Dr.Shuo Zhang

Director,Formulation R&D

Dr.Shuo Zhang-Director,Formulation R&D

Dr.Maggie Lu

Dr.Maggie Lu

Director,Clinical Pharmacology

Dr.Maggie Lu-Director,Clinical Pharmacology

闻晓光博士

Dr.Gilbert Wen

Founder/Chairman

赵大川博士

Dr.David Zhao

Chief Scientific Officer

范军博士

Dr.John Fan

Chief Technical Officer

蔡怀涵博士

Dr.Huaihan Cai

Director, Medical Affairs

张硕博士

Dr.Shuo Zhang

Director,Formulation R&D

吕敏燕医生

Dr.Maggie Lu

Director, Clinical Pharmacology

Product



US FDA Approved Product
Levetiracetam Extended Release Tablet has been approved by US FDA


US FDA Accepted Application for Approval
Lamotrigine Extended Release has been accepted by US FDA for review
NDA batch manufacture
Ibuprofen Bilayer Tablet has been conducted
Approval of clinical trials
12 INDs (Investigational New Drug) have been granted by US FDA for clinical trials
Pilot PK studies
21 human pilot PK studies have been conducted
Animal PK studies
14 animal studies have been conducted for new drug candidates
Development Timeline
Copyright Overseas Pharmaceutical, Ltd. 苏ICP备15022868号-1